metformin has been researched along with Adolescent Obesity in 48 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 9.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "Here we study whether circulating GDF-15 levels were raised by such metformin treatment and whether they related to changes in body weight and visceral fat in children with obesity." | 9.51 | A 24-month metformin treatment study of children with obesity: Changes in circulating GDF-15 and associations with changes in body weight and visceral fat. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Gómez-Vilarrubla, A; Ibañez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Prats-Puig, A; Puerto-Carranza, E; Xargay-Torrent, S, 2022) |
| "Metformin has been used in pregnancy since the 1970s." | 9.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "Metformin has shown its effectiveness in reducing body mass index (BMI) in obese children and adolescents, but relevant evidence for improving insulin resistance in overweight or obese children and adolescents is inconclusive." | 9.01 | The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. ( He, H; Sun, J; Wang, Y; Zhang, X, 2019) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 8.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone." | 8.02 | Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system. ( Concepcion, JQ; Huang, K; Tucker, LY, 2021) |
| "With the increasing incidence of childhood obesity, clinicians need to understand its comorbidities and their management." | 6.55 | Metformin Use in Children and Adolescents with Prediabetes. ( Chin, VL; Khokhar, A; Perez-Colon, S; Umpaichitra, V, 2017) |
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 5.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "Here we study whether circulating GDF-15 levels were raised by such metformin treatment and whether they related to changes in body weight and visceral fat in children with obesity." | 5.51 | A 24-month metformin treatment study of children with obesity: Changes in circulating GDF-15 and associations with changes in body weight and visceral fat. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Gómez-Vilarrubla, A; Ibañez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Prats-Puig, A; Puerto-Carranza, E; Xargay-Torrent, S, 2022) |
| "Metformin, a first-line oral antidiabetic agent that has shown promising results in terms of treating childhood and adolescent obesity, might influence the composition of the gut microbiota." | 5.41 | Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial. ( Aguilera, CM; Bueno, G; Caballero-Villarraso, J; Cañete, MD; Cañete, R; Egea-Zorrilla, A; Gil, Á; Hoyos, R; Latorre, M; Leis, R; Pastor-Villaescusa, B; Plaza-Díaz, J; Vázquez-Cobela, R, 2021) |
| "Evaluate the impact of metformin treatment during puberty, a critical window of cardiometabolic change, on insulin sensitivity (Si) and compensatory β-cell response in youth with obesity." | 5.41 | Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity. ( Hilkin, A; Kelsey, MM; Nadeau, KJ; Pyle, L; Severn, C; Utzschneider, K; Van Pelt, RE; Zeitler, PS, 2021) |
| "Metformin is increasingly used to treat gestational diabetes and type 2 diabetes in pregnancy, and in attempts to improve pregnancy outcomes in polycystic ovary syndrome and obesity." | 5.30 | Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Nossum, MCF; Salvesen, Ø; Vaage, MØ; Vanky, E; Ødegård, R, 2019) |
| "Metformin has been used in pregnancy since the 1970s." | 5.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "Prepubertal intervention with metformin reduces central adiposity and improves insulin sensitivity in non-obese catch-up SGA children." | 5.20 | Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. ( Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A, 2015) |
| "With this systematic review of RCTs, we suggest that metformin has modest but favorable effects on weight and insulin resistance and a tolerable safety profile among children and adolescents with obesity." | 5.12 | Efficacy and Safety of Metformin for Obesity: A Systematic Review. ( Aloe, S; Brunetti, VC; Filion, KB; Henderson, M; Masarwa, R; Platt, RW, 2021) |
| " Metformin seems to be safe and presents evident positive effects on insulin sensitivity, but long-term and consistent data are still missing to establish its role in the pediatric population and the possible effectiveness of other emergent treatments such as glucagon-like peptide-1 analogues, dipeptidylpeptidase-4 inhibitors, dual inhibitors of SGLT1 and SGLT2 and weight loss drugs." | 5.05 | Metabolic syndrome in children. ( Chiarelli, F; Samvelyan, S; Tagi, VM, 2020) |
| "Metformin has shown its effectiveness in reducing body mass index (BMI) in obese children and adolescents, but relevant evidence for improving insulin resistance in overweight or obese children and adolescents is inconclusive." | 5.01 | The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. ( He, H; Sun, J; Wang, Y; Zhang, X, 2019) |
| "English-language trials of benefits or harms of screening or treatment (behavior-based, orlistat, metformin) for overweight or obesity in children aged 2 through 18 years, conducted in or recruited from health care settings." | 4.95 | Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Burda, BU; Eder, M; Evans, CV; Lozano, P; O'Connor, EA; Walsh, ES, 2017) |
| "A PubMed database search was conducted, using 'metformin', 'obesity', 'insulin resistance', 'children', 'adolescents' as search terms." | 4.89 | Systematic review of metformin use in obese nondiabetic children and adolescents. ( Brufani, C; Cappa, M; Crinò, A; Fintini, D; Manco, M; Patera, PI, 2013) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 4.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone." | 4.02 | Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system. ( Concepcion, JQ; Huang, K; Tucker, LY, 2021) |
| "Use of metformin for weight loss for children in a clinical setting has not been well described; therefore, we aimed to identify characteristics of obese patients prescribed metformin in a clinical setting and evaluate changes in anthropometric measures." | 3.88 | Use of Metformin for Weight Management in Children and Adolescents With Obesity in the Clinical Setting. ( Ariza, AJ; Binns, HJ; Kadakia, RB; Kwon, S; Kyler, KE; Palac, HL, 2018) |
| "Glycemic failure rate was 75." | 2.94 | Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. ( Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM, 2020) |
| "Metformin has shown its effectiveness in treating obesity in adults." | 2.84 | Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. ( Aguilera, CM; Bueno, G; Caballero-Villarraso, J; Cañete, MD; Cañete, R; Gil, Á; Hoyos, R; Latorre, M; Leis, R; Maldonado, J; Pastor-Villaescusa, B; Plaza-Díaz, J; Vázquez-Cobela, R, 2017) |
| "Metformin is an oral anti-hyperglycemic agent that has been demonstrated to be efficacious in the treatment of diabetic and non-diabetic obese adults." | 2.82 | Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial. ( Aguilera, CM; Bueno, G; Caballero-Villarraso, J; Cañete, MD; Cañete, R; Gil, Á; Hoyos, R; Leis, R; Maldonado, J; Pastor-Villaescusa, B, 2016) |
| "When treated with metformin and an exercise program, a structured, reduced energy diet, which is either high-carbohydrate or moderate-carbohydrate with increased-protein, can achieve clinically significant improvements in obese adolescents at risk of type 2 diabetes." | 2.79 | Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial. ( Ambler, GR; Baur, LA; Briody, J; Broderick, CR; Chisholm, K; Cowell, CT; De, S; Garnett, SP; Gow, M; Ho, M; Noakes, M; Srinivasan, S; Steinbeck, K; Woodhead, HJ, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children." | 2.66 | Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. ( Kohli, R; Lin, CH, 2020) |
| "Several childhood obesity interventions are effective in improving metabolic and anthropometric measures." | 2.55 | Treatment of Pediatric Obesity: An Umbrella Systematic Review. ( Ahmed, AT; Almasri, J; Alsawas, M; Asi, N; Farah, W; Mohammed, K; Murad, MH; Prokop, LJ; Rajjo, T, 2017) |
| "With the increasing incidence of childhood obesity, clinicians need to understand its comorbidities and their management." | 2.55 | Metformin Use in Children and Adolescents with Prediabetes. ( Chin, VL; Khokhar, A; Perez-Colon, S; Umpaichitra, V, 2017) |
| "Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences." | 2.53 | Drug interventions for the treatment of obesity in children and adolescents. ( Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B, 2016) |
| "Childhood obesity is an important public health problem with increasing prevalence." | 2.50 | Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. ( Foley, C; McDonagh, MS; Ozpinar, A; Selph, S, 2014) |
| "With the rising prevalence of childhood obesity, pediatricians are increasingly called upon to treat clinically overweight children." | 2.49 | The clinical treatment of childhood obesity. ( Armstrong, SC; Dolinsky, DH; Kinra, S, 2013) |
| "Childhood and adolescent obesity has become a global epidemic." | 1.91 | [Research progresses on interventions of obesity in children and adolescents]. ( Wan, NJ; Zhang, T, 2023) |
| "Metformin (25 μmol/L) was introduced after initial 12 h with palmitate." | 1.91 | Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets. ( Aydin, B; Bergsten, P; Chowdhury, AI; Forslund, A; Shekha, M; Stenlid, R; Wen, Q, 2023) |
| " Here, an adult physiologically based pharmacokinetic (PBPK) model of metformin was scaled to pediatric populations without obesity, with overweight/obesity, and with severe obesity; a published virtual population of children and adolescents with obesity was leveraged during model evaluation." | 1.72 | Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity. ( Edginton, AN; Ford, JL; Gerhart, JG; Gonzalez, D; Hon, YY; Yanovski, JA, 2022) |
| "Although the overall rate of child and adolescent obesity has stabilized over the last decade after increasing steadily for 3 decades, obesity rates continue to increase in certain populations, such as African American girls and Hispanic boys." | 1.46 | Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Bibbins-Domingo, K; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Grossman, DC; Kemper, AR; Krist, AH; Kurth, AE; Landefeld, CS; Mangione, CM; Phipps, MG; Silverstein, M; Simon, MA; Tseng, CW, 2017) |
| " Model 2 described the inter-relationship between dosing and side effects; side effects were a significant experience for many young people, and few adhered to prescribed regimens, independently changing lifestyle and dosage to tolerate medications." | 1.42 | Adolescent experiences of anti-obesity drugs. ( Christie, D; Clifford, S; Jamieson, L; Shield, JP; Smith, F; Viner, RM; White, B; Wong, IC, 2015) |
| "Prevalence of childhood obesity is increasing and is associated with elevated long-term risk of T2D and other adverse cardio-metabolic events; however, consensus is lacking on intervention strategies aimed at reducing this risk." | 1.40 | Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes. ( Amin, R; Clayton, PE; Kendall, DL, 2014) |
| "Characteristic findings of type 1 and type 2 diabetes may be present simultaneously." | 1.40 | [Difficult diagnosis in a 17-year-old patient: Type 1 diabetes? Type 2 diabetes? Or "double diabetes"?]. ( Engelsberger, I; Warncke, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (60.42) | 24.3611 |
| 2020's | 19 (39.58) | 2.80 |
| Authors | Studies |
|---|---|
| Newman, C | 1 |
| Dunne, FP | 1 |
| Ford, JL | 1 |
| Gerhart, JG | 1 |
| Edginton, AN | 1 |
| Yanovski, JA | 2 |
| Hon, YY | 1 |
| Gonzalez, D | 1 |
| Fornes, R | 1 |
| Simin, J | 1 |
| Nguyen, MH | 1 |
| Cruz, G | 1 |
| Crisosto, N | 1 |
| van der Schaaf, M | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| Deussen, AR | 1 |
| Louise, J | 1 |
| Dodd, JM | 1 |
| Li, M | 1 |
| Liu, L | 1 |
| Kang, Y | 1 |
| Huang, S | 1 |
| Xiao, Y | 1 |
| Wan, NJ | 1 |
| Zhang, T | 1 |
| Wen, Q | 1 |
| Chowdhury, AI | 1 |
| Aydin, B | 1 |
| Shekha, M | 1 |
| Stenlid, R | 1 |
| Forslund, A | 1 |
| Bergsten, P | 1 |
| Vatopoulou, A | 1 |
| Tziomalos, K | 1 |
| Arslanian, S | 1 |
| El Ghormli, L | 1 |
| Haymond, MH | 1 |
| Chan, CL | 1 |
| Chernausek, SD | 1 |
| Gandica, RG | 1 |
| Gubitosi-Klug, R | 1 |
| Levitsky, LL | 1 |
| Siska, M | 1 |
| Willi, SM | 1 |
| Tagi, VM | 1 |
| Samvelyan, S | 1 |
| Chiarelli, F | 2 |
| Lin, CH | 1 |
| Kohli, R | 1 |
| Pastor-Villaescusa, B | 3 |
| Plaza-Díaz, J | 2 |
| Egea-Zorrilla, A | 1 |
| Leis, R | 3 |
| Bueno, G | 3 |
| Hoyos, R | 3 |
| Vázquez-Cobela, R | 2 |
| Latorre, M | 2 |
| Cañete, MD | 3 |
| Caballero-Villarraso, J | 3 |
| Gil, Á | 3 |
| Cañete, R | 3 |
| Aguilera, CM | 3 |
| Mohn, A | 1 |
| Polidori, N | 1 |
| Castorani, V | 1 |
| Comegna, L | 1 |
| Giannini, C | 1 |
| Blasetti, A | 1 |
| Raman, V | 1 |
| Foster, CM | 1 |
| Masarwa, R | 1 |
| Brunetti, VC | 1 |
| Aloe, S | 1 |
| Henderson, M | 1 |
| Platt, RW | 1 |
| Filion, KB | 1 |
| Kelsey, MM | 1 |
| Hilkin, A | 1 |
| Pyle, L | 1 |
| Severn, C | 1 |
| Utzschneider, K | 1 |
| Van Pelt, RE | 1 |
| Zeitler, PS | 1 |
| Nadeau, KJ | 1 |
| Anderson, K | 1 |
| Kelsberg, G | 1 |
| Safranek, S | 1 |
| Concepcion, JQ | 1 |
| Tucker, LY | 1 |
| Huang, K | 1 |
| Carreras-Badosa, G | 1 |
| Gómez-Vilarrubla, A | 1 |
| Mas-Parés, B | 1 |
| Martínez-Calcerrada, JM | 1 |
| Xargay-Torrent, S | 1 |
| Prats-Puig, A | 1 |
| Puerto-Carranza, E | 1 |
| Díaz-Roldán, F | 1 |
| de Zegher, F | 2 |
| Ibañez, L | 2 |
| Bassols, J | 2 |
| López-Bermejo, A | 2 |
| Rajjo, T | 1 |
| Mohammed, K | 1 |
| Alsawas, M | 1 |
| Ahmed, AT | 1 |
| Farah, W | 1 |
| Asi, N | 1 |
| Almasri, J | 1 |
| Prokop, LJ | 1 |
| Murad, MH | 1 |
| O'Connor, EA | 1 |
| Evans, CV | 1 |
| Burda, BU | 1 |
| Walsh, ES | 1 |
| Eder, M | 1 |
| Lozano, P | 1 |
| Grossman, DC | 1 |
| Bibbins-Domingo, K | 1 |
| Curry, SJ | 1 |
| Barry, MJ | 1 |
| Davidson, KW | 1 |
| Doubeni, CA | 1 |
| Epling, JW | 1 |
| Kemper, AR | 1 |
| Krist, AH | 1 |
| Kurth, AE | 1 |
| Landefeld, CS | 1 |
| Mangione, CM | 1 |
| Phipps, MG | 1 |
| Silverstein, M | 1 |
| Simon, MA | 1 |
| Tseng, CW | 1 |
| Maldonado, J | 2 |
| Kaplowitz, P | 1 |
| Scinta, W | 1 |
| Bayes, H | 1 |
| Smith, N | 1 |
| Khokhar, A | 1 |
| Umpaichitra, V | 1 |
| Chin, VL | 1 |
| Perez-Colon, S | 1 |
| Lentferink, YE | 1 |
| van der Aa, MP | 1 |
| van Mill, EGAH | 1 |
| Knibbe, CAJ | 1 |
| van der Vorst, MMJ | 1 |
| Kyler, KE | 1 |
| Kadakia, RB | 1 |
| Palac, HL | 1 |
| Kwon, S | 1 |
| Ariza, AJ | 1 |
| Binns, HJ | 1 |
| Sun, J | 1 |
| Wang, Y | 1 |
| Zhang, X | 1 |
| He, H | 1 |
| Hanem, LGE | 1 |
| Salvesen, Ø | 1 |
| Juliusson, PB | 1 |
| Carlsen, SM | 1 |
| Nossum, MCF | 1 |
| Vaage, MØ | 1 |
| Ødegård, R | 1 |
| Vanky, E | 1 |
| Ramkumar, S | 1 |
| Tandon, N | 1 |
| Brufani, C | 1 |
| Crinò, A | 1 |
| Fintini, D | 1 |
| Patera, PI | 1 |
| Cappa, M | 1 |
| Manco, M | 1 |
| Kendall, DL | 1 |
| Amin, R | 1 |
| Clayton, PE | 1 |
| McDonagh, MS | 1 |
| Selph, S | 1 |
| Ozpinar, A | 1 |
| Foley, C | 1 |
| Warncke, K | 1 |
| Engelsberger, I | 1 |
| Díaz, M | 1 |
| Garnett, SP | 1 |
| Gow, M | 1 |
| Ho, M | 1 |
| Baur, LA | 1 |
| Noakes, M | 1 |
| Woodhead, HJ | 1 |
| Broderick, CR | 1 |
| Chisholm, K | 1 |
| Briody, J | 1 |
| De, S | 1 |
| Steinbeck, K | 1 |
| Srinivasan, S | 1 |
| Ambler, GR | 1 |
| Cowell, CT | 1 |
| Adeyemo, MA | 1 |
| McDuffie, JR | 1 |
| Kozlosky, M | 1 |
| Krakoff, J | 1 |
| Calis, KA | 1 |
| Brady, SM | 1 |
| White, B | 1 |
| Jamieson, L | 1 |
| Clifford, S | 1 |
| Shield, JP | 1 |
| Christie, D | 1 |
| Smith, F | 1 |
| Wong, IC | 1 |
| Viner, RM | 1 |
| Lee, PD | 1 |
| Lustig, RH | 1 |
| Lenders, C | 1 |
| Baillargeon, J | 1 |
| Wilson, DM | 1 |
| Kelly, AS | 1 |
| Fox, CK | 1 |
| Rudser, KD | 1 |
| Gross, AC | 1 |
| Ryder, JR | 1 |
| Taylor, SA | 1 |
| Himes, R | 1 |
| Hastings, E | 1 |
| Garland, B | 1 |
| Mead, E | 1 |
| Atkinson, G | 1 |
| Richter, B | 1 |
| Metzendorf, MI | 1 |
| Baur, L | 1 |
| Finer, N | 1 |
| Corpeleijn, E | 1 |
| O'Malley, C | 1 |
| Ells, LJ | 1 |
| Dingle, E | 1 |
| Brar, PC | 1 |
| Al Khalifah, RA | 1 |
| Alnhdi, A | 1 |
| Alghar, H | 1 |
| Alanazi, M | 1 |
| Florez, ID | 1 |
| Dolinsky, DH | 1 |
| Armstrong, SC | 1 |
| Kinra, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents[NCT01775813] | Phase 4 | 104 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Family Inclusive Childhood Obesity Treatment Designed for Low Income and Hispanic Families[NCT05041855] | 658 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | |||
| Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers[NCT03781102] | 120 participants (Anticipated) | Interventional | 2019-07-01 | Suspended (stopped due to COVID19) | |||
| Mediterranean Enriched Diet for Tackling Youth Obesity[NCT04719052] | 240 participants (Anticipated) | Interventional | 2021-05-25 | Active, not recruiting | |||
| Eating Better Together: A Pilot Study[NCT05028205] | 30 participants (Anticipated) | Interventional | 2021-08-16 | Recruiting | |||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance[NCT00005669] | Phase 2 | 100 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
ALT measured in serum at each time point (NCT01775813)
Timeframe: Baseline (Tanner 2-3), Tanner 4, Tanner 5
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 25.022 | 27.059 | 26.121 | NA |
| Obese - Metformin | 52.400 | 42.545 | 39.636 | 45.000 |
| Obese - NT/Placebo | 35.194 | 44.571 | 38.650 | NA |
| Obese - Placebo | 41.125 | 51.182 | 47.500 | 50.231 |
AST measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 42.174 | 35.706 | 33.364 | NA |
| Obese - Metformin | 54.150 | 40.273 | 34.091 | 36.273 |
| Obese - NT/Placebo | 41.250 | 44.429 | 36.650 | NA |
| Obese - Placebo | 43.542 | 43.636 | 42.333 | 39.077 |
estradiol metabolite (E1c) measured in an overnight urine sample at each time point (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit-average 3 yrs after baseline
| Intervention | ng/mgCr (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 7.711 | 22.919 | 41.036 | NA |
| Obese - Metformin | 28.451 | 37.722 | 71.546 | 30.883 |
| Obese - NT/Placebo | 17.353 | 8.584 | 7.825 | 26.402 |
| Obese - Placebo | 17.353 | 8.584 | 7.825 | 26.402 |
FSH measured in overnight urine sample at time points below (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit-average 3 yrs after baseline
| Intervention | international units per milliliter (IU/m (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3.911 | 2.555 | 6.540 | NA |
| Obese - Metformin | 3.615 | 3.162 | 3.213 | 3.911 |
| Obese - NT/Placebo | 3.837 | 4.874 | 4.093 | 5.993 |
| Obese - Placebo | 3.837 | 4.874 | 4.093 | 5.993 |
LH measured in an overnight urine sample at time points below (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit (average 3 yrs after baseline)
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3.849 | 4.518 | 4.494 | NA |
| Obese - Metformin | 3.809 | 3.729 | 8.993 | 30.861 |
| Obese - NT/Placebo | 2.257 | 3.310 | 2.014 | 5.373 |
| Obese - Placebo | 2.257 | 3.310 | 2.014 | 5.373 |
DHEA-S measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | mcg/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 90.146 | 101.889 | 130.206 | NA |
| Obese - Metformin | 107.600 | 129.545 | 145.818 | 176.818 |
| Obese - NT/Placebo | 96.750 | 101.533 | 137.250 | NA |
| Obese - Placebo | 91.167 | 116.182 | 137.083 | 132.154 |
Please see primary outcome for more detail about timing of measurement. Disposition index is measured via (IVGTT) as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. It reflects the product of outcome measures 1 and 2 (Si x AIRg). (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | x10-4/min-1 (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3750.463 | 3706.940 | 3234.061 | NA |
| Obese - Metformin | 4438.821 | 5046.218 | 3537.273 | 2539.933 |
| Obese - NT/Placebo | 4195.921 | 3269.039 | 2897.244 | NA |
| Obese - Placebo | 4286.209 | 2897.689 | 3194.773 | 3627.762 |
Estradiol measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 22.375 | 50.583 | 57.382 | NA |
| Obese - Metformin | 14.750 | 23.364 | 48.000 | 69.636 |
| Obese - NT/Placebo | 15.722 | 35.867 | 42.800 | NA |
| Obese - Placebo | 15.833 | 44.545 | 48.833 | 70.923 |
HbA1c measured by HPLC at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | mmol/mol (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 5.139 | 5.200 | 5.233 | NA |
| Obese - Metformin | 5.400 | 5.570 | 5.473 | 5.691 |
| Obese - NT/Placebo | 5.336 | 5.627 | 5.476 | NA |
| Obese - Placebo | 5.336 | 5.627 | 5.500 | 5.515 |
Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 51.442 | 51.667 | 46.909 | NA |
| Obese - Metformin | 41.368 | 42.273 | 43.000 | 41.818 |
| Obese - NT/Placebo | 39.306 | 39.455 | 38.944 | NA |
| Obese - Placebo | 38.917 | 39.455 | 39.333 | 40.923 |
hsCRP measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 1.001 | 0.305 | 1.015 | NA |
| Obese - Metformin | 3.962 | 1.841 | 0.961 | 2.667 |
| Obese - NT/Placebo | 2.523 | 4.530 | 3.331 | NA |
| Obese - Placebo | 3.117 | 4.357 | 3.985 | 3.958 |
As measured by IVGTT as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | µIU/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 583.535 | 783.191 | 680.858 | NA |
| Obese - Metformin | 2368.931 | 2157.349 | 1804.026 | 1667.713 |
| Obese - NT/Placebo | 1877.895 | 1951.323 | 2103.309 | NA |
| Obese - Placebo | 1858.16 | 1996.867 | 2013.628 | 1943.542 |
As measured by in intravenous glucose tolerance test (IVGTT) as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. Patients are randomized to receive metformin or placebo at Tanner stage 2-3 of puberty. They are reassessed at Tanner 4 and again at Tanner 5. At that point, the treatment is stopped and they are reassessed 6 months after stopping treatment to see if effects of treatment persist. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | x10-4/min-1/mIU/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 8.559 | 6.661 | 6.438 | NA |
| Obese - Metformin | 2.985 | 2.873 | 2.990 | 2.182 |
| Obese - NT | 3.425 | 1.995 | 2.082 | NA |
| Obese - Placebo | 3.756 | 1.868 | 2.383 | 3.017 |
IGF-1 measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 313.500 | 405.389 | 398.000 | NA |
| Obese - Metformin | 281.700 | 410.300 | 404.800 | 395.818 |
| Obese - NT/Placebo | 262.278 | 370.800 | 389.800 | NA |
| Obese - Placebo | 243.042 | 380.273 | 351.833 | 319.692 |
Leptin measured in serum at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 5.956 | 5.964 | 8.338 | NA |
| Obese - Metformin | 32.215 | 29.791 | 31.182 | 48.445 |
| Obese - NT/Placebo | 32.097 | 36.867 | 38.155 | NA |
| Obese - Placebo | 33.917 | 44.036 | 47.642 | 53.200 |
Liver fat percent. Measured in a subset (10 per group) by fast MRI technique (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | percentage of liver mass (Mean) | |
|---|---|---|
| Baseline | Tanner 5 | |
| Normal Weight | 1.376 | 2.208 |
| Obese - Metformin | 13.765 | 10.327 |
| Obese - Placebo | 8.290 | 8.291 |
| Obese NT/Placebo | 8.290 | 8.219 |
Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 79.488 | 75.367 | 78.485 | NA |
| Obese - Metformin | 83.779 | 81.818 | 75.000 | 86.545 |
| Obese - NT/Placebo | 86.533 | 96.636 | 96.222 | NA |
| Obese - Placebo | 88.583 | 96.636 | 97.667 | 103.154 |
% body fat measured by DXA at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | percentage of body fat (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 24.883 | 25.054 | 25.500 | NA |
| Obese - Metformin | 43.826 | 40.610 | 39.964 | 41.418 |
| Obese - NT/Placebo | 42.126 | 43.380 | 42.889 | NA |
| Obese - Placebo | 44.700 | 44.264 | 44.555 | 43.962 |
SHBG measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | nmol/l (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 61.958 | 50.417 | 43.500 | NA |
| Obese - Metformin | 17.550 | 19.545 | 16.455 | 17.273 |
| Obese - NT/Placebo | 20.417 | 17.200 | 16.250 | NA |
| Obese - Placebo | 18.958 | 16.364 | 15.750 | 15.538 |
Testosterone measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 108.625 | 145.972 | 235.559 | NA |
| Obese - Metformin | 41.050 | 121.727 | 117.909 | 150.727 |
| Obese - NT/Placebo | 35.278 | 87.933 | 158.300 | NA |
| Obese - Placebo | 30.125 | 89.364 | 165.750 | 152.692 |
Percent Visceral Fat, Measured in a subset (10 per group) by single slice MRI (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | Percent (Mean) | |
|---|---|---|
| Baseline | Tanner 5 | |
| Normal Weight | 7.647 | 6.322 |
| Obese - Metformin | 12.076 | 10.079 |
| Obese - NT/Placebo | 12.007 | 12.236 |
| Obese - Placebo | 12.007 | 12.236 |
Change in body fat mass measured by air displacement plethysmography (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -1.51 |
| Placebo Plus Weight Reduction Counseling | 1.81 |
Change in body fat mass by Dual Energy X-Ray Absorptiometry (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 0.48 |
| Placebo Plus Weight Reduction Counseling | 1.88 |
Change in body weight (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 1.47 |
| Placebo Plus Weight Reduction Counseling | 4.85 |
Change in body weight as determined by body mass index (kg/m2) (NCT00005669)
Timeframe: 6 months
| Intervention | kg/m2 (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.78 |
| Placebo Plus Weight Reduction Counseling | 0.32 |
Change in Body Mass Index standard deviation score (BMI-SDS) determined using tables created by the CDC in 2000. BMI-SDS is a unitless transformation of the body mass index (measured in kg divided by the squared height in meters) using the L M S method. Possible values range from -3 to +3. See http://www.cdc.gov/growthcharts/percentile_data_files.htm for details. (NCT00005669)
Timeframe: 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.11 |
| Placebo Plus Weight Reduction Counseling | -0.07 |
18 reviews available for metformin and Adolescent Obesity
| Article | Year |
|---|---|
Metformin for pregnancy and beyond: the pros and cons.
Topics: Administration, Oral; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational W | 2022 |
Management of obesity in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Insulin Resistance; Life Style; Metformin; Pediatric O | 2020 |
Metabolic syndrome in children.
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Cardiovascular Diseases; Child; Dipeptidyl-Pepti | 2020 |
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Bariatric Surgery; Child; Child, Preschool; Cysteami | 2020 |
Efficacy and Safety of Metformin for Obesity: A Systematic Review.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Child, Preschool; Humans; Hypoglycemic Agen | 2021 |
Is metformin effective for reducing weight in obese or overweight adolescents?
Topics: Adolescent; Body Mass Index; Body Weight; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity; | 2021 |
Treatment of Pediatric Obesity: An Umbrella Systematic Review.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Blood Gl | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Metformin Use in Children and Adolescents with Prediabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pediatric Obes | 2017 |
The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Female; Huma | 2019 |
Type 2 diabetes mellitus in children and youth.
Topics: Adolescent; Child; Cross-Sectional Studies; Developing Countries; Diabetes Complications; Diabetes M | 2013 |
Systematic review of metformin use in obese nondiabetic children and adolescents.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Life Style; Metformin; Ped | 2013 |
Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger.
Topics: Adolescent; Body Mass Index; Child; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity; Rando | 2014 |
Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
Topics: Anti-Obesity Agents; Body Mass Index; Child; Directive Counseling; Exenatide; Humans; Hypoglycemic A | 2016 |
Gastrointestinal Conditions in the Obese Patient.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Constipation; Contraceptiv | 2016 |
Drug interventions for the treatment of obesity in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; | 2016 |
The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Drug Monitoring; Drug Therapy, Combination; Evi | 2017 |
The clinical treatment of childhood obesity.
Topics: Adolescent; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; | 2013 |
12 trials available for metformin and Adolescent Obesity
| Article | Year |
|---|---|
Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity.
Topics: Child; Diet; Female; Follow-Up Studies; Humans; Life Style; Metformin; Overweight; Pediatric Obesity | 2023 |
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
Topics: Adolescent; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2020 |
Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial.
Topics: Adolescent; Age Factors; Bacteria; Child; Double-Blind Method; Female; Gastrointestinal Microbiome; | 2021 |
Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity.
Topics: Adipose Tissue; Adolescent; Body Composition; Body Mass Index; Child; Diabetes Mellitus, Type 2; Dou | 2021 |
A 24-month metformin treatment study of children with obesity: Changes in circulating GDF-15 and associations with changes in body weight and visceral fat.
Topics: Body Mass Index; Body Weight; Child; Double-Blind Method; Growth Differentiation Factor 15; Humans; | 2022 |
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Double-Blind Method; Female | 2017 |
Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial.
Topics: Adult; Body Mass Index; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hypoglycemic Age | 2019 |
Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.
Topics: Abdominal Fat; Adiposity; Anti-Obesity Agents; Biomarkers; Body Mass Index; Child; Cohort Studies; D | 2015 |
Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial.
Topics: Adolescent; Blood Pressure; Body Composition; Body Mass Index; Child; Combined Modality Therapy; Die | 2014 |
Effects of metformin on energy intake and satiety in obese children.
Topics: Appetite Depressants; Body Mass Index; Child; Child Behavior; Child Nutritional Physiological Phenom | 2015 |
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PREDICTS INSULIN SENSITIVITY AND INSULIN AREA-UNDER-THE-CURVE IN OBESE, NONDIABETIC ADOLESCENTS.
Topics: Adolescent; Area Under Curve; Biomarkers; Blood Glucose; Female; Glucose Tolerance Test; Humans; Ins | 2016 |
Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial.
Topics: Adolescent; Age Factors; Biomarkers; Body Mass Index; Child; Clinical Protocols; Double-Blind Method | 2016 |
18 other studies available for metformin and Adolescent Obesity
| Article | Year |
|---|---|
Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity.
Topics: Adolescent; Adult; Child; Humans; Metformin; Models, Biological; Obesity, Morbid; Overweight; Pediat | 2022 |
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newbo | 2022 |
Circulating THBS1: A Risk Factor for Nonalcoholic Fatty Liver Disease in Obese Children.
Topics: Animals; Child; Cross-Sectional Studies; Humans; Leptin; Liver; Metformin; Mice; Mice, Inbred C57BL; | 2023 |
[Research progresses on interventions of obesity in children and adolescents].
Topics: Adolescent; Child; Gastrectomy; Gastric Bypass; Humans; Metformin; Obesity, Morbid; Pediatric Obesit | 2023 |
Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets.
Topics: Adolescent; Carboxypeptidase H; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Ins | 2023 |
Hyperglycaemic hyperosmolar state in an obese prepubertal girl with type 2 diabetes: case report and critical approach to diagnosis and therapy.
Topics: Blood Glucose; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Com | 2021 |
Metformin Treatment of Pediatric Obesity.
Topics: Child; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity | 2021 |
Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system.
Topics: Adolescent; Body Mass Index; Child; Delivery of Health Care, Integrated; Humans; Hypoglycemic Agents | 2021 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Is There a Role for Metformin in the Treatment of Childhood Obesity?
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pediatric Obesity | 2017 |
Insulin Resistance and Hunger in Childhood Obesity: A Patient and Physician's Perspective.
Topics: Adolescent; Adult; Attitude to Health; Child; Child, Preschool; Female; Humans; Hunger; Hypoglycemic | 2017 |
Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study.
Topics: Adolescent; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; M | 2018 |
Use of Metformin for Weight Management in Children and Adolescents With Obesity in the Clinical Setting.
Topics: Adolescent; Child; Female; Humans; Hypoglycemic Agents; Linear Models; Male; Metformin; Pediatric Ob | 2018 |
Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metformin; Pe | 2014 |
Metformin in obesity.
Topics: Adolescent; Body Mass Index; Child; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity | 2014 |
[Difficult diagnosis in a 17-year-old patient: Type 1 diabetes? Type 2 diabetes? Or "double diabetes"?].
Topics: Adolescent; Autoantibodies; Blood Glucose; C-Peptide; Cation Transport Proteins; Comorbidity; Diabet | 2014 |
Adolescent experiences of anti-obesity drugs.
Topics: Adolescent; Anti-Obesity Agents; Child; Comprehension; Drug Substitution; Fear; Female; Humans; Lact | 2015 |
Prediabetes in Obese Adolescents.
Topics: Adolescent; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metfor | 2017 |